Cascara sagrada laxatives
This article was originally published in The Tan Sheet
Executive Summary
FDA will not defer enforcement action against manufacturers of OTC laxatives containing cascara sagrada, agency states in Sept. 2 letter to Atlanta law firm Arnall Golden Gregory denying citizen petition. Decision barring laxatives containing ingredient from initial entry into interstate commerce as of Nov. 5, 2002 stands, FDA says. Agency reply follows recent letter to AHPA denying association's request to move cascara sagrada from Category III to Category I (1"The Tan Sheet" Aug. 4, 2003, p. 11)...
You may also be interested in...
Aloe, Cascara Sagrada Safety In Laxatives Still Needs Supporting Data – FDA
Data on aloe and cascara sagrada from the German Commission E monographs, World Health Organization reviews and the National Toxicology Program are insufficient to support the safety and efficacy of the ingredients in OTC laxatives, FDA concludes in a July 3 letter to the American Herbal Products Association
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.